|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
intravenous
|
|
gptkbp:approvedBy
|
1976
|
|
gptkbp:ATCCode
|
gptkb:C07AB03
|
|
gptkbp:bioavailability
|
40-50%
|
|
gptkbp:brand
|
gptkb:Atenololum
gptkb:Tenormin
Atenix
|
|
gptkbp:CASNumber
|
gptkb:29122-68-7
|
|
gptkbp:contraindication
|
asthma
severe bradycardia
cardiogenic shock
|
|
gptkbp:eliminatedIn
|
renal
|
|
gptkbp:eliminationHalfLife
|
6-7 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:hasMolecularFormula
|
C14H22N2O3
|
|
gptkbp:hasUNII
|
50VV3VW0TI
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
D00203
|
|
gptkbp:isApprovedDrug
|
true
|
|
gptkbp:isBetaBlocker
|
true
|
|
gptkbp:isNotMetabolizedBy
|
gptkb:CYP450
|
|
gptkbp:KEGGID
|
gptkb:D00203
|
|
gptkbp:legalStatus
|
Rx-only
|
|
gptkbp:mechanismOfAction
|
beta-1 adrenergic receptor antagonist
|
|
gptkbp:meltingPoint
|
158-160°C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
266.34
|
|
gptkbp:name
|
gptkb:Atenolol
|
|
gptkbp:notRecommendedFor
|
pregnancy
breastfeeding
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
DB00335
2249
2866
|
|
gptkbp:sideEffect
|
dizziness
fatigue
bradycardia
cold extremities
|
|
gptkbp:solubility
|
water soluble
|
|
gptkbp:synonym
|
gptkb:4-(2-hydroxy-3-isopropylaminopropoxy)phenylacetamide
|
|
gptkbp:usedFor
|
gptkb:arrhythmia
myocardial infarction
hypertension
angina pectoris
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:amphotericin_B
|
|
gptkbp:bfsLayer
|
6
|